Clinical utility of cerebrospinal fluid biomarkers in the evaluation of cognitive impairment: a systematic review and meta-analysis

被引:17
|
作者
Hazan, Jemma [1 ]
Wing, Michelle [1 ]
Liu, Kathy Y. [1 ]
Reeves, Suzanne [1 ]
Howard, Robert [1 ]
机构
[1] UCL, Div Psychiat, London, England
来源
关键词
DEMENTIA; ALZHEIMER'S DISEASE; CSF; ALZHEIMERS-DISEASE; CSF BIOMARKERS; DIAGNOSTIC IMPACT; PHOSPHORYLATED TAU; COST-EFFECTIVENESS; DEMENTIA; AMYLOID-BETA(1-42); PERFORMANCE; FRAMEWORK;
D O I
10.1136/jnnp-2022-329530
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background The analytical and clinical validity of cerebrospinal (CSF) biomarkers has been extensively researched in dementia. Further work is needed to assess the ability of these biomarkers to improve diagnosis, management and health outcomes in the clinical setting Objectives To assess the added value and clinical utility of CSF biomarkers in the diagnostic assessment of cognitively impaired patients under evaluation for Alzheimer's disease (AD). Methods Systematic literature searches of Medline, EMBASE, PsycINFO and Web of Science research databases were conducted on 17 December 2022. Data from relevant studies were extracted and independently screened for quality using a tool for bias. Clinical utility was measured by clinicians' changes in diagnosis, diagnostic confidence and patient management (when available), after their examination of patients' CSF biomarkers. Cost-effectiveness was assessed by consideration of additional cost per patient and quality-adjusted life years. Results Searches identified 17 studies comprising 2090 patient participants and 593 clinicians. The meta-analysis revealed that clinicians' use of CSF biomarkers resulted in a pooled percentage change in diagnosis of 25% (95% CI 14 to 37), an increase in diagnostic confidence of 14% (95% CI 9 to 18) and a pooled proportion of patients whose management changed of 31% (95% CI 12 to 50). CSF biomarkers were deemed cost-effective, particularly in memory services, where pre-test AD prevalence is higher compared with a primary care setting. Conclusions CSF biomarkers can be a helpful additional diagnostic tool for clinicians assessing patients with cognitive impairment. In particular, CSF biomarkers consistently improved clinicians' confidence in diagnosing AD and influenced on diagnostic change and patient management. Further research is needed to study the clinical utility of blood-based biomarkers in the clinical setting.
引用
收藏
页码:113 / 120
页数:8
相关论文
共 50 条
  • [1] Novel fluid biomarkers for mild cognitive impairment: A systematic review and meta-analysis
    Gaur, Amish
    Rivet, Luc
    Mah, Ethan
    Bawa, Kritleen K.
    Gallagher, Damien
    Herrmann, Nathan
    Lanctot, Krista L.
    AGEING RESEARCH REVIEWS, 2023, 91
  • [2] Migraine biomarkers in cerebrospinal fluid: A systematic review and meta-analysis
    van Dongen, Robin M.
    Zielman, Ronald
    Noga, Marek
    Dekkers, Olaf M.
    Hankemeier, Thomas
    van den Maagdenberg, Arn M. J. M.
    Terwindt, Gisela M.
    Ferrari, Michel D.
    CEPHALALGIA, 2017, 37 (01) : 49 - 63
  • [3] Migraine biomarkers in cerebrospinal fluid and blood: a systematic review and meta-analysis
    van Dongen, R. M.
    Zielman, R.
    Noga, M.
    Dekkers, O. M.
    Hankemeier, T.
    van den Maagdenberg, A. M. J. M.
    Terwindt, G. M.
    Ferrari, M. D.
    CEPHALALGIA, 2015, 35 : 261 - 262
  • [4] Cerebrospinal Fluid Biomarkers for Diagnosing Neuropsychiatric SLE: A Systematic Review and Meta-Analysis
    Ahmadi, Seyed-Foad
    Zahmatkesh, Golara
    Majed, Masoud
    Desai, Sheetal
    ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] Neurofilament light chain in cerebrospinal fluid or blood as a biomarker for mild cognitive impairment A systematic review and meta-analysis
    Zhang, Jing
    Cheng, Hongjiang
    Liu, Wei
    Li, Huimin
    Song, Yi
    Jia, Longbin
    MEDICINE, 2022, 101 (09) : E28932
  • [6] Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis
    Shengri Cong
    Chunchen Xiang
    Hailong Wang
    Shuyan Cong
    Journal of Neurology, 2021, 268 : 2703 - 2712
  • [7] Diagnostic utility of fluid biomarkers in multiple system atrophy: a systematic review and meta-analysis
    Cong, Shengri
    Xiang, Chunchen
    Wang, Hailong
    Cong, Shuyan
    JOURNAL OF NEUROLOGY, 2021, 268 (08) : 2703 - 2712
  • [8] Potential Biomarkers for Post-Stroke Cognitive Impairment: A Systematic Review and Meta-Analysis
    Kim, Ka Young
    Shin, Ki Young
    Chang, Keun-A
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (02)
  • [9] Blood biomarkers for post-stroke cognitive impairment: A systematic review and meta-analysis
    Ma, Yuxia
    Chen, Yanru
    Yang, Tingting
    He, Xiang
    Yang, Yifang
    Chen, Junbo
    Han, Lin
    JOURNAL OF STROKE & CEREBROVASCULAR DISEASES, 2024, 33 (08):
  • [10] Sarcopenia and cognitive impairment: A systematic review and meta-analysis
    Peng, Tao-Chun
    Chen, Wei-Liang
    Wu, Li-Wei
    Chang, Yaw-Wen
    Kao, Tung-Wei
    CLINICAL NUTRITION, 2020, 39 (09) : 2695 - 2701